A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

Haematologica

Volumn 87, Issue 8, 2002, Pages 804-807

  Garcia Manero, Guillermo ^a   Faderl, Stefan ^a   Giles, Francis ^a   Thomas, Deborah ^a   Cortes, Jorge ^a   O'Brien, Susan ^a   Davis, Jan ^a   Kantarjian, Hagop M ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Amifostine; Cytarabine; Idarubicin; Myelodysplastic syndrome

Indexed keywords

AMIFOSTINE; CYTARABINE; IDARUBICIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE TOXICITY; ADULT; ARTICLE; CANCER GRADING; CELL PROTECTION; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; EXPERIENCE; HEART DISEASE; HUMAN; HYPOTENSION; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; REMISSION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MIDDLE AGED; MYELOID LEUKEMIA; RECURRENT DISEASE; REFRACTORY ANEMIA WITH EXCESS BLASTS; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AMIFOSTINE; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOVASCULAR DISEASES; CYTARABINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGE; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035986757     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. NCCN practice guidelines for acute myelogenous leukemia
2. Treatment of acute myelogenous leukemia and myelodysplastic syndromes
3. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
4. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties
5. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721
6. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats
7. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML
8. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
9. Continual reassessment method: A practical design for phase 1 clinical trials in cancer